Predicting Favorable Outcomes in Hospitalized Covid-19 Patients

December 22, 2022 updated by: NYU Langone Health
Testing use of predictive analytics to predict which COVID-19+ patients are at low risk for an adverse event (ICU transfer, intubation, mortality, hospice discharge, re-presentation to the ED, oxygen requirements exceeding nasal cannula at 6L/Min) in the next 96 hours

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

To assess if display of low risk of adverse event in EPIC can safely reduce length of stay and plan for discharge.

Study Type

Observational

Enrollment (Actual)

1415

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • New York, New York, United States, 10016
        • NYU Langone Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult hospitalized COVID19+ patients predicted to have no adverse event at 96 events with a threshold at 90% PPV, with at least one low risk during their admission who are discharged alive and have not been in the ICU

Description

Inclusion Criteria: Adult hospitalized COVID19+ patients predicted to have no adverse event at 96 events with a threshold at 90% PPV, with at least one low risk during their admission who are discharged alive and have not been in the ICU

Exclusion Criteria: Age < 18 years not hospitalized for COVID19+.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Quality improvement - Display
Display of risk score/ colored flag in Epic patient list column; will be viewable to all frontline workers
Other: EPIC risk score display
Display of risk score/ colored flag in Epic patient list column
No Display
No display ("hidden") of risk score/ colored flag in Epic patient list column; not viewable to all frontline workers

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction in days from first low-risk score to discharge
Time Frame: 96 Hours
Reduction in days from first low-risk score to discharge
96 Hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction in length of stay (LOS)
Time Frame: 96 hours
Reduction in LOS for green patients that have not been in the ICU
96 hours
Reduction in GTD vs. LOS
Time Frame: 96 hours
Reduction in GTD vs. LOS for all green patients discharged alive vs all patients discharged alive
96 hours
No change in 30 day re-ED presentation or hospital admission rate for cohort
Time Frame: 96 hours
No change in 30 day re-ED presentation or hospital admission rate for cohort
96 hours

Other Outcome Measures

Outcome Measure
Time Frame
Re-presentation to ED
Time Frame: 96 hours
96 hours
Readmission to hospital
Time Frame: 96 hours
96 hours
Mortality
Time Frame: 96 hours
96 hours
Postdischarge mortality
Time Frame: 96 hours
96 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

NYU Langone Health

Investigators

  • Principal Investigator: Jonathan Austrian, MD, NYU Langone Health

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 15, 2020

Primary Completion (Actual)

December 7, 2021

Study Completion (Actual)

December 7, 2021

Study Registration Dates

First Submitted

September 25, 2020

First Submitted That Met QC Criteria

September 29, 2020

First Posted (Actual)

September 30, 2020

Study Record Updates

Last Update Posted (Actual)

December 27, 2022

Last Update Submitted That Met QC Criteria

December 22, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PAU COVID19

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID

Clinical Trials on EPIC risk score display

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe